{"id":987503097,"date":"2026-07-22T22:36:51","date_gmt":"2026-07-22T22:36:51","guid":{"rendered":"https:\/\/boracdmo.com\/?p=987503097"},"modified":"2026-07-22T22:37:50","modified_gmt":"2026-07-22T22:37:50","slug":"bora-pharmaceuticals-and-onconic-therapeutics-sign-manufacturing-agreement-to-support-u-s-clinical-development-of-jaqbo-tablets","status":"publish","type":"post","link":"https:\/\/boracdmo.com\/bora-pharmaceuticals-and-onconic-therapeutics-sign-manufacturing-agreement-to-support-u-s-clinical-development-of-jaqbo-tablets\/","title":{"rendered":"Bora Pharmaceuticals and Onconic Therapeutics Sign Manufacturing Agreement to Support U.S. Clinical Development of JAQBO Tablets"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Bora to manufacture and package clinical trial drug product for JAQBO tablets as Onconic advances U.S. Phase 3 preparation for gastroesophageal reflux disease (GERD)<\/i><\/b><\/h3>\n

Maple Grove, Minnesota (July 23, 2026) \u2013 <\/strong>Bora Pharmaceuticals Co., Ltd.<\/a> (\u201cBora\u201d; TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, and Onconic Therapeutics<\/a> (KOSDAQ: 476060), a Korea-based biopharmaceutical company, have entered into a manufacturing agreement to support the U.S. clinical development of JAQBO potassium-competitive acid blocker tablets, or P-CAB, treatment for GERD, which affects approximately 20% of the U.S. population<\/a>. As treatment needs continue to evolve, P-CAB therapies are gaining attention for their rapid and sustained acid suppression profile.<\/p>\n


<\/p>\n

Under the agreement, Bora\u2019s newest OSD facility in Maple Grove, Minn., will also support quality control, stability testing, and the preparation of related chemistry, manufacturing, and controls documentation for Onconic\u2019s planned U.S. Phase 3 clinical trial of JAQBO.<\/p>\n


<\/p>\n

\u201cFor companies preparing for U.S. clinical development and commercialization, the right manufacturing partner can make a meaningful difference in how quickly a program moves forward,\u201d said Bobby Sheng, Chairman of Bora Group and CEO of Bora. \u201cWe are proud to support Onconic as it prepares JAQBO for planned U.S. clinical development, and this collaboration reflects Bora\u2019s commitment to helping innovative companies move with confidence into highly regulated markets.\u201d<\/p>\n


<\/p>\n

JAQBO was independently developed by Onconic Therapeutics and approved in Korea in April 2024 as Korea\u2019s 37th domestically developed new drug. Since its launch in October 2024, JAQBO has shown strong prescription growth in Korea and has continued to expand its global development and commercialization partnerships across multiple international markets.<\/p>\n


<\/p>\n

\u201cThis collaboration with a global CDMO is an important preparatory step in establishing the manufacturing, quality, and stability data package required for JAQBO\u2019s U.S. clinical development,\u201d said John Kim, CEO Onconic Therapeutics. \u201cBased on our prescription growth in Korea and overseas commercialization achievements, we will proceed with U.S. development preparation without delay and strengthen JAQBO\u2019s global competitiveness.\u201d<\/p>\n


<\/p>\n

For Bora, the partnership builds on the company\u2019s global CDMO momentum and its continued focus on helping pharmaceutical and biotech partners optimize product development, accelerate launches, and scale supply to meet patient needs.<\/p>\n

# # #<\/p>\n

About Bora Pharmaceuticals<\/b><\/p>\n

Founded in 2007, Bora Pharmaceuticals Co., Ltd. (\u201cBora\u201d or \u201cthe Company\u201d, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of \u201cContributing to Better Health All Over the World\u201d. Operating under a \u201cDual Engine\u201d model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients\u2019 quality of life.<\/p>\n

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success \u201ccertain,\u201d Bora sets new standards in the pharmaceutical and CDMO industries.<\/p>\n

For more information, please visit www.bora-corp.com<\/a>.<\/p>\n

About Onconic Therapeutics<\/b><\/p>\n

Onconic Therapeutics is a Korea-based biopharmaceutical company focused on the development and commercialization of innovative therapies. The company developed JAQBO, a P-CAB class treatment for gastroesophageal reflux disease, which was approved in Korea in April 2024 and launched in October 2024. JAQBO\u2019s global development and commercialization partnerships continue to expand across major international markets, including China, India, Latin America, Northern Europe, Southeast Asia, and other regions.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Bora to manufacture and package clinical trial drug product for JAQBO tablets as Onconic advances U.S. Phase 3 preparation for gastroesophageal reflux disease (GERD)<\/p>\n","protected":false},"author":43,"featured_media":987503098,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[58],"tags":[],"class_list":["post-987503097","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business"],"aioseo_notices":[],"acf":[],"_links":{"self":[{"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/posts\/987503097","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/users\/43"}],"replies":[{"embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/comments?post=987503097"}],"version-history":[{"count":9,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/posts\/987503097\/revisions"}],"predecessor-version":[{"id":987503108,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/posts\/987503097\/revisions\/987503108"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/media\/987503098"}],"wp:attachment":[{"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/media?parent=987503097"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/categories?post=987503097"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/tags?post=987503097"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}